Case report: development of Hodgkin's disease in patient receiving long-term administration of dacarbazine and interleukin-2 for metastatic melanoma.
Flaherty
L E
LE
Division of Hematology and Oncology, Wayne State University, School of Medicine, Detroit, Mich.
Schwert
R
R
Redman
B G
BG
D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006689:Hodgkin Disease / Q000139:chemically induced*; D006801:Humans; D007376:Interleukin-2 / Q000009:adverse effects* / Q000627:therapeutic use; D008545:Melanoma / Q000188:drug therapy* / Q000556:secondary; D008875:Middle Aged
D007376:Interleukin-2; D003606:Dacarbazine